In yesterday’s Wall Street session, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares traded at $129.86, up 4.35% from the previous session.
SRPT stock price is now 2.61% away from the 50-day moving average and 13.63% away from the 200-day moving average. The market capitalization of the company currently stands at $12.27B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $157, Piper Sandler recently initiated with Overweight rating for Sarepta Therapeutics Inc (NASDAQ: SRPT). On May 28, 2024, RBC Capital Mkts Downgraded its previous ‘Outperform’ rating to ‘Sector Perform’ on the stock reducing its target price from $157 to quote $142, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Murray Dallan, Chief Customer Officer sold 3,635 shares of the company’s stock on May 02 ’24. The stock was sold for $508,900 at an average price of $140.00. Upon completion of the transaction, the Chief Customer Officer now directly owns 18,125 shares in the company, valued at $2.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’24, Director Boor Kathryn Jean sold 761 shares of the business’s stock. A total of $93,550 was realized by selling the stock at an average price of $122.93. This leaves the insider owning 7,516 shares of the company worth $0.98 million. A total of 6.10% of the company’s stock is owned by insiders.
During the past 12 months, Sarepta Therapeutics Inc has had a low of $55.25 and a high of $146.68. As of last week, the company has a debt-to-equity ratio of 1.44, a current ratio of 4.05, and a quick ratio of 3.44. The fifty day moving average price for SRPT is $126.6368 and a two-hundred day moving average price translates $114.3623 for the stock.
The latest earnings results from Sarepta Therapeutics Inc (NASDAQ: SRPT) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.27, beating analysts’ expectations of -1.78 by 1.51. This compares to -$5.86 EPS in the same period last year. The net profit margin was 1.20% and return on equity was 2.02% for SRPT. The company reported revenue of $413.46 million for the quarter, compared to $253.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 63.1 percent. For the current quarter, analysts expect SRPT to generate $388.36M in revenue.
